<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00112710</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000429610</org_study_id>
    <secondary_id>CRUK-BTOG2-LU3005</secondary_id>
    <secondary_id>EU-20510</secondary_id>
    <nct_id>NCT00112710</nct_id>
  </id_info>
  <brief_title>Gemcitabine in Combination With Either Cisplatin or Carboplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer</brief_title>
  <official_title>A British Thoracic Oncology Group Phase III Trial of Gemcitabine Plus Cisplatin at 80mg/m Versus Gemcitabine Plus Carboplatin At 50 mg/m Versus Gemcitabine Plus Carboplatin AUC 6 in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as gemcitabine, cisplatin, and carboplatin, work&#xD;
      in different ways to stop the growth of tumor cells, either by killing the cells or by&#xD;
      stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill&#xD;
      more tumor cells. It is not yet known whether giving gemcitabine together with cisplatin is&#xD;
      more effective than giving gemcitabine together with carboplatin in treating non-small cell&#xD;
      lung cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is studying gemcitabine and cisplatin to see how&#xD;
      well they work compared to gemcitabine and carboplatin in treating patients with stage III or&#xD;
      stage IV non-small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare the efficacy of gemcitabine in combination with 2 different doses of cisplatin&#xD;
           vs carboplatin, in terms of survival time, in patients with stage IIIB or IV non-small&#xD;
           cell lung cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare symptom control and quality of life of patients treated with these regimens.&#xD;
&#xD;
        -  Compare response in patients treated with these regimens.&#xD;
&#xD;
        -  Compare the dose intensity of these regimens in these patients.&#xD;
&#xD;
        -  Compare the ratio of courses of treatment given as in-patient vs out-patient in these&#xD;
           patients.&#xD;
&#xD;
        -  Compare the intensity and number and duration of toxic episodes in patients treated with&#xD;
           these regimens.&#xD;
&#xD;
        -  Compare cost and cost-effectiveness of these regimens in these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to WHO&#xD;
      performance status (0 vs 1 or 2), disease stage (IIIB vs IV), and participating center.&#xD;
      Patients are randomized to 1 of 3 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive gemcitabine IV over 30 minutes on days 1 and 8 and cisplatin IV&#xD;
           over 1 hour on day 1.&#xD;
&#xD;
        -  Arm II: Patients receive gemcitabine as in arm I and cisplatin (at a lower dose than in&#xD;
           arm I) IV over 1 hour on day 1.&#xD;
&#xD;
        -  Arm III: Patients receive gemcitabine as in arm I and carboplatin IV over 1 hour on day&#xD;
           1.&#xD;
&#xD;
      In all arms, treatment repeats every 21 days for 2 courses. Patients are reassessed after 2&#xD;
      courses. Patients with responding disease or stable disease with symptom improvement receive&#xD;
      2 additional courses of therapy in the absence of disease progression or unacceptable&#xD;
      toxicity. Patients with disease progression or stable disease without symptom improvement are&#xD;
      removed from the study.&#xD;
&#xD;
      Quality of life is assessed at baseline, on day 1 of courses 2-4, at completion of study&#xD;
      treatment, and then monthly for 6 months.&#xD;
&#xD;
      After completion of study treatment, patients are followed monthly for 6 months and then&#xD;
      periodically thereafter for survival.&#xD;
&#xD;
      Peer Reviewed and Funded or Endorsed by Cancer Research UK&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 1,350 patients (450 per treatment arm) will be accrued for this&#xD;
      study within 6 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2005</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Length of survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptom control and quality of life as measured by the EORTC Quality of Life Questionnaire Core 30 Items and Lung Cancer supplement 13 together with EuroQol-5 domain questionnaire</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment response as measured by RECIST criteria</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose intensity of chemotherapy</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of treatment courses given as in-patient versus out-patient</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity as measured by CTCAE v3.0</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment cost</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">1350</enrollment>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed non-small cell lung cancer (NSCLC), meeting&#xD;
             1 of the following stage criteria:&#xD;
&#xD;
               -  Stage IIIB disease* that is not suitable for radical radiotherapy&#xD;
&#xD;
               -  Stage IV disease* NOTE: *Radiographically verified&#xD;
&#xD;
          -  At least 1 measurable lesion by clinical examination or radiography&#xD;
&#xD;
          -  No mixed histologies of small cell lung cancer and NSCLC&#xD;
&#xD;
          -  No clinically apparent brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  WHO 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC ≥ 3,000/mm³&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Hemoglobin ≥ 10 g/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  AST &lt; 3 times upper limit of normal (ULN) (5 times ULN if liver metastases are&#xD;
             present)&#xD;
&#xD;
          -  Alkaline phosphatase &lt; 3 times ULN&#xD;
&#xD;
          -  Bilirubin &lt; 1.5 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine clearance ≥ 60 mL/min (by Wright equation) OR ≥ 70 mL/min (by ^51Cr-EDTA&#xD;
             clearance)&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Able and willing to participate in the quality of life assessment&#xD;
&#xD;
          -  No pre-existing neuropathy &gt; grade 2&#xD;
&#xD;
          -  No other malignancy that would preclude study treatment or study comparisons&#xD;
&#xD;
          -  No evidence of severe or uncontrolled systemic disease, significant clinical disorder,&#xD;
             or laboratory finding that would preclude study participation&#xD;
&#xD;
          -  No psychiatric disorder that would preclude study participation&#xD;
&#xD;
          -  No other condition that would preclude study compliance&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior chemotherapy, including neoadjuvant or adjuvant chemotherapy&#xD;
&#xD;
          -  No other concurrent cytotoxic chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No concurrent hormonal therapy except contraceptives or replacement steroids&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Recovered from prior surgery&#xD;
&#xD;
          -  Prior surgical resection for NSCLC allowed&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 12 weeks since prior investigational agents and recovered&#xD;
&#xD;
          -  No other concurrent specific antitumor therapy&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hugh Jarrett</last_name>
    <role>Study Chair</role>
    <affiliation>Institute of Clinical Research - Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Clinical Research - Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>England</state>
        <zip>B15 2TT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hugh Jarrett</last_name>
      <phone>44-121-414-6425</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Birmingham Heartlands Hospital</name>
      <address>
        <city>Birmingham</city>
        <state>England</state>
        <zip>B9 5SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joyce Thompson</last_name>
      <phone>44-121-766-6611</phone>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2007</verification_date>
  <study_first_submitted>June 2, 2005</study_first_submitted>
  <study_first_submitted_qc>June 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2005</study_first_posted>
  <last_update_submitted>August 23, 2013</last_update_submitted>
  <last_update_submitted_qc>August 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2013</last_update_posted>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

